Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced Cancer

NCT05902988 is registered in ClinicalTrials.gov with Volastra Therapeutics, Inc. as lead sponsor.

NCT NCT05902988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05902988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced Cancer
Lead sponsor
Volastra Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 18, 2023
Completion date
December 31, 2026
Enrollment
200 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, chromosomal instability, endometrium cancer, head and neck squamous cell carcinoma, high grade serous adenocarcinoma of ovary, ovarian carcinosarcoma, squamous non-small-cell lung cancer, triple negative breast cancer, uterine carcinosarcoma, uterine serous carcinoma